Positive Phase III for Lundbeck/Biotie's nalmefene
This article was originally published in Scrip
Lundbeck and Biotie Therapies have reported positive data from two out of three Phase III trials evaluating the alcohol dependence therapy candidate, nalmefene. The companies expect to submit a marketing authorisation application in Europe in the second half of this year pending successful completion of the third Phase III trial, a short-term efficacy study, for which data should be available in the second quarter.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.